Dermata Therapeutics, Inc.
DRMA
$6.45
$0.2183.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.95% | -7.08% | -9.32% | -2.12% | 47.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.96% | 44.17% | 78.02% | 66.46% | 40.65% |
| Operating Income | 26.96% | -44.17% | -78.02% | -66.46% | -40.65% |
| Income Before Tax | 26.50% | -47.65% | -84.57% | -66.28% | -39.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.50% | -47.65% | -84.57% | -66.28% | -39.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.50% | -47.65% | -84.57% | -66.28% | -39.92% |
| EBIT | 26.96% | -44.17% | -78.02% | -66.46% | -40.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 93.67% | 86.27% | 74.77% | 55.68% | -- |
| Normalized Basic EPS | 93.67% | 86.27% | 74.77% | 55.68% | -- |
| EPS Diluted | 93.67% | 86.27% | 74.77% | 55.68% | -- |
| Normalized Diluted EPS | 93.67% | 86.27% | 74.77% | 55.68% | -- |
| Average Basic Shares Outstanding | 1,060.97% | 974.06% | 630.05% | 276.11% | -- |
| Average Diluted Shares Outstanding | 1,060.97% | 974.06% | 630.05% | 276.11% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |